Showing results (561-570 of 1,019) with videos related to

Sort By:
Pageof 102
Clinicoeconomics and Outcomes Research : CEOR|November 30, 2016
Patient-reported financial barriers to adherence to treatment in neurologyLidia Mvr Moura, Eli L Schwamm, Valdery Moura Junior, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 7, 2016
Prioritizing health system and disease burden factors: an evaluation of the net benefit of transferring health technology interventions to different districts in ZimbabweShepherd Shamu, Simbarashe Rusakaniko, Charles Hongoro
Clinicoeconomics and Outcomes Research : CEOR|March 16, 2017
Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health unitsValentina Perrone, Diego Sangiorgi, Stefano Buda, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 28, 2014
Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesionsBarry Weinstock, Raymond Dattilo, Tiffini Diage
Clinicoeconomics and Outcomes Research : CEOR|March 11, 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 25, 2017
Relative cost-effectiveness of using a liquid human milk fortifier in preterm infants in the USJulian F Guest, Fernando Moya, Paula M Sisk, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 1, 2017
Cost-effectiveness of SQ® HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in GermanyWilliam Green, Jörg Kleine-Tebbe, Ludger Klimek, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 6, 2016
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in SpainLuis Felipe Casado, Amparo Burgos, Eva González-Haba, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 6, 2016
Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in ThailandUnchalee Permsuwan, Piyameth Dilokthornsakul, Surasak Saokaew, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 4, 2016
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian districtEnnio Polilli, Valeria Cento, Umberto Restelli, et al.
Pageof 102